Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pinacidil
- Development stage
- Discontinued
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
Pinacidil is a cyanoguanidine small molecule antihypertensive drug that acts as an ATP-sensitive potassium channel opener in vascular smooth muscle cells. By increasing potassium permeability, it causes peripheral vasodilatation of arterioles and decreases peripheral vascular resistance, resulting in reduced blood pressure. Pinacidil was approved by the FDA in 1989 but has since been discontinued. It is classified as a guanidine derivative and was primarily indicated for the treatment of hypertension[1][2][4][5].
- Brand names
- Pindac
- Other names
- pinacidil hydratepinacidil monohydrate
02
Targets
SUR1 (Sulfonylurea receptor 1)KATP channel (ATP-sensitive potassium channel)
Beyond the preview
Go deeper on pinacidil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pinacidil.